These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38334125)

  • 1. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
    Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
    Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
    Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
    J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
    Apps JR; Martinez-Barbera JP
    Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
    Zhou J; Zhang C; Pan J; Chen L; Qi ST
    Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
    Martinez-Barbera JP
    Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma.
    Gonzalez-Meljem JM; Haston S; Carreno G; Apps JR; Pozzi S; Stache C; Kaushal G; Virasami A; Panousopoulos L; Mousavy-Gharavy SN; Guerrero A; Rashid M; Jani N; Goding CR; Jacques TS; Adams DJ; Gil J; Andoniadou CL; Martinez-Barbera JP
    Nat Commun; 2017 Nov; 8(1):1819. PubMed ID: 29180744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
    Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
    Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma.
    Yang J; Hou Z; Wang C; Wang H; Zhang H
    Cancer Gene Ther; 2018 Oct; 25(9-10):227-239. PubMed ID: 29681617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
    Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
    Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
    Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
    Front Immunol; 2022; 13():949509. PubMed ID: 36091021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of cellular senescence in paediatric pituitary tumours.
    Gonzalez-Meljem JM; Martinez-Barbera JP
    EBioMedicine; 2024 Jan; 99():104905. PubMed ID: 38043401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization.
    Xu C; Wu J; Ye J; Si Y; Zhang J; Wu B; Pan L; Fu J; Ren Q; Xie S; Tang B; Xiao Y; Hong T
    Cell Death Dis; 2024 Jun; 15(6):439. PubMed ID: 38906852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
    Hengartner AC; Prince E; Vijmasi T; Hankinson TC
    Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adamantinomatous craniopharyngioma as a model to understand paracrine and senescence-induced tumourigenesis.
    Gonzalez-Meljem JM; Martinez-Barbera JP
    Cell Mol Life Sci; 2021 May; 78(10):4521-4544. PubMed ID: 34019103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic Control of Adamantinomatous Craniopharyngiomas.
    Marrero-Gutiérrez J; Bueno AC; Martins CS; Coeli-Lacchini FB; Silva-Júnior RMP; Marques Gonçalves GH; Ozaki JGO; de Almeida E Silva DC; Wildemberg LE; da Silva Antunes XL; Dos Santos AC; Machado HR; Santos MV; Moreira AC; Gadelha MR; Vêncio RZN; Antonini SRR; de Castro M
    J Clin Endocrinol Metab; 2024 Sep; 109(10):e1867-e1880. PubMed ID: 38181427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of SRY-related HMG Box Transcription Factors (Sox) 2 and 9 in Craniopharyngioma Subtypes and Surrounding Brain Tissue.
    Thimsen V; John N; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Knosp E; Losa M; Buslei R; Hölsken A
    Sci Rep; 2017 Nov; 7(1):15856. PubMed ID: 29158570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
    Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
    Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.